{
    "674e70cf-32fd-39f6-bc7c-14d8b269e969": {
        "uuid": "674e70cf-32fd-39f6-bc7c-14d8b269e969",
        "title": "AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know",
        "publisher": "Zacks",
        "link": "https://finance.yahoo.com/news/abbvie-abbv-dips-more-broader-214509269.html",
        "providerPublishTime": 1655243109,
        "type": "STORY"
    },
    "13d22d22-1e5d-3967-83e8-37d9a94ba05d": {
        "uuid": "13d22d22-1e5d-3967-83e8-37d9a94ba05d",
        "title": "Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata",
        "publisher": "Zacks",
        "link": "https://finance.yahoo.com/news/lilly-lly-incytes-olumiant-gets-144102793.html",
        "providerPublishTime": 1655217662,
        "type": "STORY"
    },
    "88a8ccf5-2af6-398d-ac9b-7ee41fbd7ba6": {
        "uuid": "88a8ccf5-2af6-398d-ac9b-7ee41fbd7ba6",
        "title": "Baron Funds: \u201cWe Retain Conviction in AbbVie (ABBV)\u201d",
        "publisher": "Insider Monkey",
        "link": "https://finance.yahoo.com/news/baron-funds-retain-conviction-abbvie-120413838.html",
        "providerPublishTime": 1655208253,
        "type": "STORY"
    },
    "ac4068c5-5fdf-3640-9b32-8b6b2174afac": {
        "uuid": "ac4068c5-5fdf-3640-9b32-8b6b2174afac",
        "title": "The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T",
        "publisher": "Zacks",
        "link": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-berkshire-095109577.html",
        "providerPublishTime": 1655200269,
        "type": "STORY"
    },
    "99dbb58f-f875-38bb-9426-11c899553a54": {
        "uuid": "99dbb58f-f875-38bb-9426-11c899553a54",
        "title": "Top Analyst Reports for Berkshire Hathaway, AbbVie & TotalEnergies",
        "publisher": "Zacks",
        "link": "https://finance.yahoo.com/news/top-analyst-reports-berkshire-hathaway-184906510.html",
        "providerPublishTime": 1655146146,
        "type": "STORY"
    },
    "02e4142f-d184-3e77-b0be-1b077267f3dd": {
        "uuid": "02e4142f-d184-3e77-b0be-1b077267f3dd",
        "title": "AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial",
        "publisher": "Benzinga",
        "link": "https://finance.yahoo.com/news/abbvie-genmab-present-epcoritamab-data-162550456.html",
        "providerPublishTime": 1655137550,
        "type": "STORY"
    },
    "34cf026b-3d8e-3262-85d4-6dd3bedc2cc1": {
        "uuid": "34cf026b-3d8e-3262-85d4-6dd3bedc2cc1",
        "title": "Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics",
        "publisher": "GlobeNewswire",
        "link": "https://finance.yahoo.com/news/sirona-biochem-announces-exclusive-global-120000162.html",
        "providerPublishTime": 1655121600,
        "type": "STORY"
    },
    "5bd2bb3b-1a8d-3835-9ca7-6f1d82ac06f6": {
        "uuid": "5bd2bb3b-1a8d-3835-9ca7-6f1d82ac06f6",
        "title": "AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody\u00ae-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress",
        "publisher": "PR Newswire",
        "link": "https://finance.yahoo.com/news/abbvie-announces-breaking-results-phase-124500437.html",
        "providerPublishTime": 1654951500,
        "type": "STORY"
    }
}